Kynurenine/Tryptophan Ratio in Hypertension Associated to Obstructive Sleep Apnea

Exclusion Criteria

• •Self-reported pregnancy or breastfeeding.
• •Patients on haemodialysis or peritoneal dialysis.
• •Chronic liver disease with Child-Pugh score B or higher.
• •Hypertension attributed to renal artery stenosis, primary hyperaldosteronism, pheochromocytoma, Cushing's syndrome, coarctation of aorta.
• •History of any OSA surgical treatment to the palatal and hypopharyngeal regions, notably uvulopalatopharyngoplasty surgery (UPPP), palatal radio frequency ablation, tonsillectomy, lingual tonsillectomy, partial glossectomy, tongue base radio frequency ablation, genioglossal advancement, hyoid suspension, maxillomandibular advancement surgery (MMA) and active use of hypoglossal nerve stimulator.
• •Patients with a good adherence to CPAP, defined as the use of CPAP for at least 4 hours/night on 70% of nights during the last 3 months.
• •Pulmonary hypertension.
• •Current diagnosed oncological disease.
• •Patients with known chronic or acute infectious diseases.
• •Other current severe progressive or uncontrolled disease which in the judgement of the investigator renders the patient unsuitable for the study
• •CONTROLS (individuals without hypertension with and without OSA) For each case, an age and gender-matched control will be selected.
• •Pregnancy or breastfeeding.
• •Patients on haemodialysis or peritoneal dialysis.
• •Chronic liver disease with Child-Pugh score b or higher.
• •History of any OSA surgical treatment to the palatal and hypopharyngeal regions, notably uvulopalatopharyngoplasty surgery (UPPP), palatal radio frequency ablation, tonsillectomy, lingual tonsillectomy, partial glossectomy, tongue base radio frequency ablation, genioglossal advancement, hyoid suspension, maxillomandibular advancement surgery (MMA) and active use of hypoglossal nerve stimulator.
• •Patients with a good adherence to CPAP, defined as the use of CPAP for at least 4 hours/night on 70% of nights during the last 3 months.
• •Pulmonary hypertension.
• •Current diagnosed oncological disease.
• •Patients with known chronic or acute infectious diseases.
• •Patients with known chronic or acute infectious diseases.
• •Other current severe progressive or uncontrolled disease which in the judgement of the investigator renders the patient unsuitable for the study.